Ionis Pharmaceuticals, Inc. (FRA:ISI)

Market Cap	11.27B +121.1%
Revenue (ttm)	824.14M +20.4%
Net Income	-218.48M
EPS	-1.37
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150
Average Volume	83
Open	67.92
Previous Close	67.20
Day's Range	67.92 - 68.78
52-Week Range	22.73 - 71.68
Beta	n/a
RSI	55.85
Earnings Date	Feb 18, 2026

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 1,069
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ISI

Financial Performance

In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.

Financial numbers in USD